Neonatal alloimmune thrombocytopenia is a rare but potentially life threatening condition in newborns. It can cause bleeding in the brain and long-term effects. Treatment usually involves a ...

Neonatal alloimmune thrombocytopenia (NAIT) is a rare blood disorder that occurs when the maternal immune system attacks the baby's platelets, causing a low platelet count. Learn more here.

Neonatal alloimmune thrombocytopenia (NAIT) is a rare yet potentially life‐threatening condition caused by maternal sensitisation to fetal platelet antigens, most notably human platelet antigen 1a.

Rallybio Corporation (NASDAQ: RLYB) announced preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212 to prevent fetal and neonatal alloimmune thrombocytopenia. The data ...

Rallybio's shares slumped ahead of the opening bell Tuesday after the clinical-stage biotechnology company dropped its development program on prevention of fetal and neonatal alloimmune ...

Rallybio Corporation (NASDAQ: RLYB) says clinical proof-of-concept has been achieved in Phase 1b study for RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Rallybio Corporation, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases ...

Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

NEW HAVEN, Conn. — Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients ...

The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & Johnson's (J&J) nipocalimab for treating individuals with moderate-to-severe ...